PremiumCompany AnnouncementsSSY Group Expands Ophthalmic Product Line with New Approval SSY Group Gains Approval for New Drug Production SSY Group Reports Decline in Q1 2025 Financial Performance PremiumCompany AnnouncementsSSY Group’s Lornoxicam Gains Approval in China SSY Group’s Allopurinol Gains Approval for Market Release SSY Group Expands Pharmaceutical Portfolio with New Approvals PremiumCompany AnnouncementsSSY Group Gains Approval for Arbidol Hydrochloride Tablets SSY Group Limited Reports 2024 Annual Results Amid Challenging Market Conditions SSY Group Announces Final Dividend for 2024